Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMolina Kanuma Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C9974-A

    Kanuma (sebelipase alfa) Coverage Criteria

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C9974-A alerts

    Get alerted when Policy C9974-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization requirements for intravenous Kanuma (sebelipase alfa) in members with lysosomal acid lipase deficiency, including Wolman disease and cholesteryl ester storage disease.

    Policy Summary
    PayerMolina Healthcare
    PolicyKanuma (sebelipase alfa) Coverage Criteria
    Policy CodePolicy C9974-A
    Change TypeNo material change
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization documentation confirming lysosomal acid lipase deficiency, baseline disease activity, member age, qualified prescriber status, and requested dosing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 month+Minimum member age
    12 monthsInitial authorization
    12 monthsContinuation authorization
    J2840HCPCS code
    IV infusion

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Administration
    Not coveredOther uses

    Coverage Criteria

    Continuation Therapy

    Covered for continuation when all of the following criteria are met:

    Continuation therapy

    • The member has documented lysosomal acid lipase deficiency, including Wolman disease or cholesteryl ester storage disease.
    • Improvement in symptoms and/or laboratory values has been achieved or sustained from baseline.

      Examples include AST, ALT, triglycerides, LDL-C, growth, biochemical markers, or organomegaly, as applicable to the member's presentation.

    • The prescriber attests to, or clinical review finds, no intolerable adverse effects or drug toxicity.

      Examples of adverse effects include hypersensitivity reactions or anaphylaxis, abdominal pain, fever, chills, pruritus, rash, or vomiting.

    • The member's current Kanuma dose based on clinical response is documented.

    All uses of Kanuma (sebelipase alfa) other than treatment of lysosomal acid lipase deficiency are considered experimental or investigational and are subject to Molina’s Off-Label policy.

    Coding and Dosing Information

    FDA-approved indication diagnosis codeICD-10Covered
    E75.5Other lipid storage disorders
    HCPCS CodeHCPCSCovered
    J2840Injection, sebelipase alfa, 1 mg
    Member age
    Minimum covered age1 month of age
    Age restrictionCoverage is limited to members 1 month of age and older
    Eligible membersMembers must be at least 1 month old for Kanuma coverage
    Pediatric and adult dose
    Standard dose1 mg/kg administered once every other week as an IV infusion
    Escalated doseMay increase to 3 mg/kg every other week for patients who do not achieve an optimal clinical response
    Suboptimal response indicators

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required for Kanuma (sebelipase alfa). Initial authorization is approved for 12 months when the required diagnosis, testing, baseline evaluation, treatment goals, and other medical-necessity documentation are submitted and criteria are met.

    • Documented lysosomal acid lipase deficiency (LAL-D), including Wolman disease or cholesteryl ester storage disease (CESD).
    • Required diagnostic confirmation, baseline disease activity evaluation, and treatment goals must be submitted with the initial request.
    Prior Authorization

    Continuation Authorization

    Continuation authorization is approved for 12 months when the member has achieved or sustained improvement from baseline and therapy remains safe and medically appropriate.

    • Document improvement in symptoms and/or laboratory values, such as AST, ALT, triglycerides, or LDL-C.
    • The prescriber must attest, or the clinical reviewer must find, no intolerable adverse effects or drug toxicity, including hypersensitivity reactions.

    Disease Background

    Lysosomal acid lipase deficiency is an autosomal recessive lysosomal storage disorder caused by deficient or absent lysosomal acid lipase activity resulting from mutations in the LIPA gene. Impaired enzyme activity causes lipid accumulation in tissues including the liver, spleen, intestines, and blood vessel walls, which may lead to dyslipidemia, liver disease, malabsorption, growth failure, fibrosis, cirrhosis, and potentially liver failure. The condition includes Wolman disease, an early-onset, rapidly progressive infantile form that may cause malabsorption, growth failure, hepatomegaly, adrenal insufficiency, and death during the first year of life, and cholesteryl ester storage disease, a generally milder, later-onset form that may present in childhood or adulthood with gastrointestinal symptoms, hepatosplenomegaly, elevated transaminases, dyslipidemia, hepatic fibrosis, or cirrhosis. Kanuma is an enzyme replacement therapy intended to address the underlying enzyme deficiency.

    Key Disease Definitions

    Wolman disease
    DefinitionAn early-onset, rapidly progressive form of lysosomal acid lipase deficiency
    Typical presentationOften presents during infancy, around 2 to 4 months of age
    Clinical characteristicsComplete enzyme deficiency may cause malabsorption, growth failure, hepatomegaly, adrenal cortical insufficiency, and death within the first year of life
    Cholesteryl ester storage disease
    DefinitionA milder, later-onset form of lysosomal acid lipase deficiency
    Typical presentationMay present in early childhood or later in life
    Clinical characteristics

    Initial Therapy

    Initial Therapy Criteria

    Initial therapy is covered when all diagnostic, documentation, prescriber, age, and dosing requirements are met.

    Initial Kanuma therapy

    • Diagnosis

      • The member has a documented diagnosis of lysosomal acid lipase deficiency, including Wolman disease or cholesteryl ester storage disease.
      • ONE of the following confirmatory tests

        • Decreased relative lysosomal acid lipase activity is demonstrated by a dried blood spot test or leukocyte testing.

          Documentation required.

        • Molecular genetic testing of the LIPA gene confirms the diagnosis.

          Documentation required.

    Continuation of Therapy

    Continuation of Therapy

    Continuation therapy is covered when all criteria below are met.

    Continuation of therapy

    • The member continues treatment for documented lysosomal acid lipase deficiency, including Wolman disease or cholesteryl ester storage disease.
    • Improvement in symptoms and/or laboratory values has been achieved or sustained from baseline.

      Response measures may include AST, ALT, triglycerides, LDL-C, growth, biochemical markers, or organomegaly, as applicable.

    • No intolerable adverse effects or drug toxicity are present, as attested by the prescriber or determined by clinical review.

      Examples include hypersensitivity reactions or anaphylaxis, abdominal pain, fever, chills, pruritus, rash, or vomiting.

    • The member's current dose, based on clinical response, is documented and remains appropriate for ongoing treatment.

    Dosing and Quantity Limits

    Kanuma (sebelipase alfa)
    Standard dose1 mg/kg administered once every other week
    Route and frequencyIV infusion administered once every other week
    Escalation limitMay increase to 3 mg/kg every other week for suboptimal clinical response
    Kanuma for infants with rapidly progressive disease presenting within the first 6 months of life
    Initial weekly dose1 mg/kg administered once weekly by IV infusion
    First escalationMay increase to 3 mg/kg once weekly for patients who do not achieve an optimal clinical response
    Maximum labeled escalation

    Administration Site Requirements

    Billing Rule

    Use an approved infusion-center setting

    Administer infused Kanuma in a non-hospital facility-based location under Molina’s Site of Care program. The Specialty Medication Administration Site of Care Coverage Criteria applies.

    Policy Summary
    PayerMolina Healthcare
    PolicyKanuma (sebelipase alfa) Coverage Criteria
    Policy CodePolicy C9974-A
    Change TypeNo material change
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization documentation confirming lysosomal acid lipase deficiency, baseline disease activity, member age, qualified prescriber status, and requested dosing.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dosing InformationAuthorization and Documentation RequirementsDisease BackgroundKey Disease DefinitionsInitial TherapyContinuation of TherapyDosing and Quantity LimitsAdministration Site Requirements
    Poor growth, deteriorating biochemical markers, or abnormal lipid metabolism parameters such as LDL-C or triglycerides
    Infant rapidly progressive disease dose
    Initial infant dose1 mg/kg administered once weekly as an IV infusion
    First escalationMay increase to 3 mg/kg once weekly for patients who do not achieve an optimal clinical response
    Further escalationMay further increase to 5 mg/kg once weekly for continued suboptimal clinical response
  1. Submit documentation of the member’s current dose based on clinical response.
  2. Documentation Required

    Qualified Prescriber Required

    The drug must be prescribed by, or in consultation with, a qualified specialist experienced in the relevant disease or treatment.

    • Acceptable prescribers or consultants include a board-certified endocrinologist, gastroenterologist, hepatologist, clinical geneticist, or specialist experienced in treating inborn errors of metabolism.
    • If prescribed in consultation, submit consultation notes with both the initial request and each reauthorization request.
    Note

    Age Requirement

    Coverage is limited to members who are 1 month of age or older.

    • Minimum age: 1 month.
    Documentation Required

    Diagnostic Confirmation

    Submit documentation confirming LAL-D through acceptable enzyme or molecular testing.

    • Decreased lysosomal acid lipase activity relative to enzyme activity by either a dried blood spot (DBS) test or leucocyte testing.
    • Alternatively, molecular genetic testing of the LIPA gene may confirm the diagnosis.
    • Diagnostic documentation is required.
    Documentation Required

    Baseline Disease Activity and Treatment Goals

    Before initial treatment, the prescriber must document a baseline evaluation of disease activity and the goals of treatment so efficacy can be assessed at renewal.

    • Include relevant baseline measures, such as hypercholesterolemia, decreased HDL, AST, and ALT.
    • Use the baseline disease measures and stated goals to evaluate response at reauthorization.
    Documentation Required

    Consultation and Current-Dose Documentation

    Submit the required specialist consultation documentation and the member’s current dose when applicable.

    • Consultation notes are required with the initial request and reauthorization requests when the prescriber is not the qualified specialist.
    • Document the current dose based on clinical response.
    • Labeled dose increases may be considered for suboptimal response, including poor growth, deteriorating biochemical or lipid markers, or, in rapidly progressive infants, persistent or worsening organomegaly.
    Documentation Required

    Supporting Records and Dosing Data

    Molina may require complete medical records and dosing data to establish medical necessity and determine coverage.

    • Provide patient records, test results, provider credentials, complete medical rationale, and other documentation requested for the coverage determination.
    • When dosing is based on weight, body surface area, or another member-specific measurement, submit that data as part of the medical-necessity review.
    • For pediatric and adult members, the labeled dose is 1 mg/kg by IV infusion once every other week; it may increase to 3 mg/kg every other week for suboptimal clinical response.
    Denial Risk

    Non-Covered or Investigational Use

    Uses of Kanuma outside treatment of lysosomal acid lipase deficiency are considered experimental or investigational and are handled under Molina’s Off-Label policy.

    • Coverage is limited to the policy’s LAL-D indication.
    • Other uses follow Molina’s Off-Label policy.
    Denial Risk

    Documentation and Billing Risks

    Molina may deny reimbursement or take other appropriate action when submitted documentation does not support medical necessity, non-investigational use, benefit eligibility, or appropriate billing.

    • Insufficient records, test results, provider credentials, or dosing information may support denial.
    • Molina may deny or recover claim payments for inappropriate billing or services that are not covered benefits.
    • Providers must use industry-standard coding practices; code listings do not guarantee coverage and may vary by state or line of business.
    May include gastrointestinal symptoms, hepatosplenomegaly, elevated transaminase levels, dyslipidemia, hepatic fibrosis, or cirrhosis
    Lysosomal acid lipase deficiency
    Disease definitionAn autosomal recessive lysosomal storage disorder
    Genetic basisCaused by mutations affecting the LIPA gene
    Enzyme deficiencyThe genetic defect causes a marked decrease or loss of lysosomal acid lipase enzyme activity
  3. Documentation

    • The prescriber submits a baseline disease activity evaluation and treatment goals for use in evaluating efficacy at renewal.

      Relevant measures may include hypercholesterolemia, decreased HDL, AST, and ALT.

  4. Prescriber

    • The drug is prescribed by, or in consultation with, a board-certified endocrinologist, gastroenterologist, hepatologist, clinical geneticist, or specialist experienced in the treatment of inborn errors of metabolism.

      Consultation notes must be submitted with the initial request when prescribed in consultation.

  5. Age

    • The member is 1 month of age or older.≥ 1 month of age
  6. Dosing

    • For pediatric and adult members, the requested dose is 1 mg/kg administered once every other week by IV infusion; it may increase to 3 mg/kg every other week for suboptimal clinical response.
    • For an infant with rapidly progressive disease presenting within the first 6 months of life, the requested dose is 1 mg/kg administered once weekly by IV infusion; it may increase to 3 mg/kg once weekly and then 5 mg/kg once weekly for continued suboptimal clinical response.
  7. Dose increases may be considered for suboptimal clinical response, including poor growth, deteriorating biochemical markers or lipid parameters, or persistent or worsening organomegaly in rapidly progressive infantile disease.

    May further increase to 5 mg/kg once weekly for continued suboptimal clinical response